Ed Addison

There appears to be a "Superstar Effect" in healthcare and biomedical AI research right now. A small percentage of publications are truly novel methods contributions that introduce new capabilities or behaviors; whereas a majority of contemporary research publications are focused on implementation science to assess the real-world utility and performance of new methods. This dynamic seems different from prior eras, when the translational infrastructure for implementing novel AI methods was largely unavailable. While methods research often captures more attention and accolades, both types of research are critical – novel methods without implementation science lacks translatability; implementation science without novel methods lacks novelty. If our goal is to invent and deploy transformative AI methods in real-world healthcare and life sciences contexts, we ought to continue encouraging and rewarding stellar implementation science work alongside breakthrough methods development.

90

3 Comments

Honored and grateful to have shared in this important discussion on #responsibleinnovation with Mike Walker, Sarah Glaven, Colin Zick and Nagisa Sakurai, PhD, MBA moderated by the exceptional and insightful, Lori Ellis (Katz). SAS is committed to providing the tools developed with #NIST standards that support researchers and analysts across all industries develop, deploy and monitor analytical models that save lives while reducing and mitigating bias. Join or start the conversation today in your organization! Ask important questions: 🧠 Who will be impacted positively or negatively by this model? 🧠 Are there vulnerable persons ir populations that could be negatively impacted? 🧠 What are the ramifications of this model on underrepresented groups? 🧠 How can we quantify bias? 🧠 What is our mitigation plan to address any harm as a result of this bias? 🧠 How does this model perform overall and in subgroups? Thank you, Lori Ellis (Katz) for inviting SAS to share our work and for so eloquently capturing the essence of our conversation. Thank you, BioSpace for publishing on this crucial topic. Trustworthy AI and Responsible Innovation - there are so many ways to improve and save lives. #sassaveslives #itsjustwhatwedo

13

M13 is thrilled to lead the Series A in RadiantGraph which is focused on personalization in healthcare. As we continue to invest in early stage companies it is abundantly clear that the biggest indicator of success is the founder and his or her ability to execute on their vision of the future. In this case, I don't think I have seen much better founder-market fit than we have with founder and CEO Anmol Madan. We believe in his vision: in order to have the best patient outcomes in healthcare we need increased personalization and AI is the breakthrough to get us there. Anmol started one of the pioneering digital health companies Ginger and then was Chief Data Scientist at Livongo and Teledoc. He has done it all: early stage, late stage, public company. And he deeply understands the nuances of the healthcare market from all angles which is critical for success. While there are many players building healthcare-specific AI capabilities, RadiantGraph is focused on outcomes: The platform is already processing personalization models for more than 3.5 million people, despite launching just last year. Excited to partner with my friend Adam D'Augelli and the great True Ventures again and Morgan Blumberg who has been deep in the healthcare market with me for many years. More on our thesis in the blog below. https://lnkd.in/evDDmC3W

72

4 Comments

Big healthcare AI news yesterday as Tempus AI received the first-ever CPT code for an algorithm-only analysis of previously-sequenced, laboratory developed test transcriptomic data. TLDR: AI molecular phenotyping has a new business model. The PurISTSM test uses RNA profiling to identify molecular subtypes in patients with advanced pancreatic ductal adenocarcinoma, which may inform first-line therapy selection and management. While I'm skeptical that payer balance sheets are going to solve the "who pays for healthcare AI" problem, the reimbursement pipes for clinical AI are maturing. I am surprised to see more progress for usage-based vs. performance-based models given the many challenges with FFS economics. It will be interesting to see how payers assess the "medical necessity" and therefore reimbursability of clinical AI as these models come to market. https://t.co/eLe18SmihV

420

9 Comments

This edition of Orrick’s life sciences series reviews key venture investment trends in Q2 2024 and features a roundtable on ARPA-H, which funds high-impact biomedical research. https://lnkd.in/gEEXNwpf

1

In our latest publication in Health, Management, Policy, and Innovation – "Why AI Is Good for Our Health but May Hurt Our Wallets," we examine how current regulatory frameworks, reimbursement structures, and business models for AI in healthcare are decoupled, creating an environment in which AI may significantly increase costs without necessarily improving outcomes. We recommend three interconnected reforms to unlock the full potential of healthcare AI: (1) Rigorous pre- and post-deployment evaluation to verify proposed clinical value, (2) Development of assessment standards through shared guidelines, and (3) Strategic alignment of AI deployment modalities with sustainable business models – "modality-business model-market" fit 👉 https://lnkd.in/d8NiczyM Sneha Shah Jain, MD, MBA, Clinical Professor and Kevin Schulman Professor of Medicine at Stanford University, Nigam Shah, Chief Data Scientist, Michael Pfeffer, Chief Information and Digital Officer, and Linda Hoff Chief Financial Officer at Stanford Health Care

106

9 Comments

CMS has published the Final Notice: Transitional Coverage for Emerging Technologies (CMS-3421-FN), effective August 12, 2024. The TCET pathway replaces MCIT, expediting Medicare coverage for FDA-designated Breakthrough Devices. Eligible devices include: - FDA-designated Breakthrough Devices - Determined to be within a Medicare benefit category - Not already the subject of an existing Medicare NCD - Not otherwise excluded from coverage through law or regulation The AltaQ team brings vast experience in the FDA Breakthrough Device program and developing clinical protocols for CED. Coverage under TCET NCD will last as needed to support informed patient and clinician decisions. #TCET #BreakthroughDevices #AltaQ

6

$1B seed funding to a new AI drug discovery startup that seemingly has nothing novel that is significant only because they have a big pharmaceutical name? Has the VC market lost its mind? To make just a 5X return will require a IPO or subsequent valuation >>$5B. I'm all for the furtherance of this field, but AI and GenAI are just tools. The product is the drug and the therapeutic risk, while reduced, is still significant. VCs just don't want to do the work anymore (of sensible investing and company building) #ai #aidrugdiscovery #aiforhealthcare #genai https://lnkd.in/ei3A5RJb

78

15 Comments

🌟 Investing in the Future of Healthcare with Edge AI 🌟 At August Global Partners, we're excited about the potential of Edge AI in revolutionizing healthcare. As Wen H. Hsieh, Ph.D., insightfully notes, "AI has huge utility for all edge applications... training is a cost, inference is revenue" ... and more ... Why Edge AI in Healthcare? - Real-Time Monitoring: Wearables equipped with Edge AI provide continuous health data, empowering proactive health management and early disease detection.    - Post-Operative Care: These devices enable remote monitoring from home, reducing hospital stays and enhancing recovery by detecting complications early. - Preventive Healthcare: By providing real-time insights, wearables help prevent health issues before they escalate, optimizing patient outcomes Edge AI is transforming healthcare into a more efficient and patient-centered system. We're committed to investing in these innovations that promise better health outcomes and value. Join us as we embrace the edge of healthcare innovation. The future is here, and it's happening now. #EdgeAI #HealthcareInnovation #PostOperativeCare #AugustGlobalPartners

78

2 Comments

Artificial intelligence (AI) revolutionizes healthcare by enhancing diagnostics, personalizing treatments, and streamlining operations. AI algorithms can analyze vast datasets, uncovering patterns that aid in early disease detection and more accurate diagnoses. This capability is particularly beneficial in medical imaging, where AI assists radiologists in identifying anomalies that might be overlooked. In drug discovery, AI expedites the identification of potential therapeutic compounds, significantly reducing the time and cost associated with bringing new drugs to market. For instance, companies like Insitro leverage machine learning to analyze extensive biological data, aiming to develop more effective treatments. Operationally, AI enhances healthcare efficiency by automating administrative tasks such as scheduling and patient record management, allowing healthcare professionals to focus more on patient care. However, the rapid integration of AI raises concerns about data privacy, algorithmic bias, and the need for transparency in AI models. Ensuring ethical AI deployment is crucial to prevent disparities in healthcare delivery. As AI continues to evolve, its potential to transform healthcare is immense. Balancing innovation with ethical considerations will be key to harnessing AI's full medical benefits.

4

Exciting news in biotech - Q1 2024 saw a 46% surge in venture funding, signaling a strong recovery. Late-stage clinical developments and innovative therapies like ADCs and radiopharmaceuticals received significant investments. The important question is what does this mean for the future of biotech? How will these trends impact the development of new therapies? And how is investor confidence changing as the IPO market sort of re-opens? Interesting thoughts to consider. You can read more on our blog: https://ow.ly/bpCF50S2iY6 #Biotech #VentureCapital #HealthcareInvestments

9

At the 2024 AI Conference, Ali Mostashari, CEO of LifeNome Inc., and Dr. D. Dr. Martin Alexander Gershon, MD, JD, MPH Managing Partner at Endeavor Endeavor Venture Fund & Venture Studio, explored the transformative impact of technology on healthcare. Their discussion highlighted AI's role in uncovering biomarkers, advancing skincare solutions, and accelerating medical research. They emphasized the integration of digital health for proactive management, underscoring AI's potential to revolutionize personalized medicine and preventive care. Ethical considerations and data privacy were also highlighted as critical in the adoption of these technologies. This insightful dialogue is a must-watch for anyone interested in the future of healthcare and longevity. Discover how AI is shaping these fields and explore new frontiers for healthier lives: https://lnkd.in/ePRvxvZB #PrecisionHealth #AIHealthcare #Longevity #HealthTech #DNA #Healthtech"

2

This is perhaps where the "U" turn for DTx starts? I'm not suggesting we will enter the highly bullish times of 2018-2021 but I think like a lot of technology cycles, this may serve as an inflection point as we look back on this 2-4 years from now. In addition to some of the additional coverage guidance around breakthrough treatments, we may see folks filing back into this space over the next 12-18 months. #dtx #digitaltherapeutics #FDA #reimbursement

4

What an incredible line-up at the Healthcare AI and Technology Investor Summit (Live/Virtual), an Endeavor Venture Fund & Venture Studio + Foley & Lardner LLP event this Wednesday 1600-2100 at Foley & Lardner's Boston office - already 1200+ registered! If you are attending live - see you there! With financial and strategic support from Endeavor Venture Funds and its Syndicate Partners this event looks to build partnerships between great hospitals, healthcare industry leaders and leading digital healthcare company entrepreneur founders for the purpose of integrating new digital technologies into hospitals and biopharma. Join to hear speakers including: Keynote Speaker: Peter Durlach, Microsoft Chief Strategy Officer, Healthcare and Life Sciences  Plenary Session Special Sessions: Valerie Fleishman, Executive Vice President and Chief Innovation Officer, Massachusetts Health & Hospital Association introducing the panelists Closing Remarks: Jim Rogers, Board of Directors Mayo Collaborative Services, Chief Business Development Officer and Senior Administrator for Generative AI, Mayo Clinic  Summit Chairman: Dr. D. Martin Alexander Gershon, MD, JD, MPH Managing Partner, Endeavor Venture Funds, White House CancerX Moonshot Advisor I am additionally pleased to see a masterclass on Burnout in the Workplace, moderated by Jenny M Fernandez, MBA, 费 珍妮 to address the all-time-high burnout in healthcare professionals that is threatening the sustainability of healthcare delivery. Look forward to hearing from experts on the short and long term solutions out there and science-based intervention programs to help rejuvenate energy, drive initiative and innovation, increase efficiency and productivity and build resilience. A critical topic from the lens of capability building and strategic workforce planning. Partnering strategically and effectively across the health ecosystem can see hospitals, biopharma, and enterprises successfully integrate remarkable healthcare AI and technologies into their business, and scale up in a sustainable manner. #digitalhealth #healthcareinnovation #healthtech #AI #GenAI #workforceplanning #FutureOfWork #burnout #resilience

25

2 Comments

Grail, a company specializing in liquid biopsy for cancer detection, is set to debut on Nasdaq amid significant challenges. CEO Bob Ragusa believes their test, Galleri, will revolutionize cancer screening when integrated into standard care. Grail's journey includes being spun out from Illumina in 2015, a failed acquisition by Illumina in 2020 due to regulatory hurdles, and subsequent re-emergence. Despite annual losses of approximately $500 million, Grail plans to seek full U.S. approval for Galleri by 2026, funded for the near future by Illumina. Click here to read more: https://bit.ly/3KWrWBZ #liquidbiopsy #nextgenerationsequencing #nasdaq #venturecapital #privateequity #deerbornedifference

6

This development is a promising step forward in the fight against lung cancer. By leveraging AI, pathologists can gain deeper insights into the disease, leading to more effective and personalized treatments. The ability to quickly and accurately analyze tissue samples can significantly impact patient outcomes, potentially reducing the high mortality rate associated with lung cancer. It’s exciting to see how technology continues to transform healthcare, offering new hope for patients and medical professionals alike. https://lnkd.in/gKEymG4U #Healthcare #AI #Medicine #Pathology #Artificial #Intelligence #Algorithms #Analysis #Lung #Cancer #Patient #Tumor #Diagnostic #Prognostic #illness #Digitalization #Treatment

48

2 Comments

“Anything in the IRA [Inflation Reduction Act] that stops us from using drugs to their maximum potential is a mistake,” says Emil Kakkis. At the Stanford Biodesign Policy Program’s Health Technology Innovation Policy Conference 2024, Kakkis and other speakers on the biotechnology panel — Jeff Allen, Ken Drazan, Peter Kolchinsky, and Peter Marks — discussed the implications of the IRA on orphan drugs, and the unintended negative consequences on patients and drug manufacturers. Acknowledging that the IRA has accomplished some important things that will make a real difference in affordability and access to healthcare, the panelists highlighted, however, that the impact for orphan drug development may be felt in the next few decades as companies limit investment/research into additional indications for orphan drugs. The panelists also discussed the potentially transformative impact of cell and gene therapies and what can be done from a regulatory perspective to support that ecosystem. If you were unable to join us, here’s a replay of the discussion https://lnkd.in/gji8d5XE Many thanks to Stanford Biodesign’s D. Michael Ackermann, director, biotechnology, who moderated the session. #healthpolicy #biotech #healthtech #SBDHealthtechInnovationPolicy

23

Platforms are in, point solutions are out as the healthcare AI category leaders come into focus this year. In conversation with Shelby Livingston at Endpoints News, I shared: 1. Why AI-first companies have the greatest platform potential and heuristics for identifying these opportunities at the earliest stages, 2. How companies are differentiating through co-development and distribution partnerships with leading healthcare institutions, and 3. Strategies for navigating anemic budgets and constrained market sizes through business model innovation such as AI-enabled services and pay for performance models Read more here: https://lnkd.in/dJWqv_zC Bessemer Venture Partners Abridge #healthcare #lifesciences #AI #generativeAI

258

14 Comments